LENZ Therapeutics (LENZ) Scheduled to Post Earnings on Wednesday

LENZ Therapeutics (NASDAQ:LENZ - Get Free Report) is scheduled to announce its earnings results after the market closes on Wednesday, May 8th. Analysts expect the company to announce earnings of ($0.84) per share for the quarter. Persons that wish to listen to the company's earnings conference call can do so using this link.

LENZ Therapeutics Trading Up 3.8 %

NASDAQ:LENZ traded up $0.60 during trading hours on Thursday, reaching $16.41. The company had a trading volume of 188,715 shares, compared to its average volume of 73,298. The company has a market cap of $59.90 million, a PE ratio of -1.05 and a beta of 0.33. LENZ Therapeutics has a 52 week low of $14.07 and a 52 week high of $29.82.

Insider Activity

In other LENZ Therapeutics news, Director Ra Capital Management, L.P. purchased 998,009 shares of the business's stock in a transaction on Thursday, March 21st. The stock was acquired at an average price of $15.03 per share, for a total transaction of $15,000,075.27. Following the purchase, the director now owns 3,319,339 shares of the company's stock, valued at approximately $49,889,665.17. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 38.40% of the company's stock.

Analyst Upgrades and Downgrades

A number of research firms recently commented on LENZ. Leerink Partnrs reiterated an "outperform" rating on shares of LENZ Therapeutics in a research report on Monday, April 15th. William Blair assumed coverage on shares of LENZ Therapeutics in a research note on Monday, April 15th. They issued an "outperform" rating on the stock. Citigroup began coverage on shares of LENZ Therapeutics in a research report on Wednesday, April 10th. They set a "buy" rating and a $34.00 target price for the company. SVB Leerink initiated coverage on LENZ Therapeutics in a research note on Monday, April 15th. They issued an "outperform" rating and a $32.00 price objective for the company. Finally, Piper Sandler started coverage on LENZ Therapeutics in a research report on Wednesday, March 27th. They set an "overweight" rating and a $28.00 target price on the stock. Five analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus price target of $31.33.

LENZ Therapeutics Company Profile

LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.